ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0551

Metabolic Intermediate Dimethyl-Alpha-Ketoglutarate Is a Novel Repressor of Pathogenic Myofibroblast Reprogramming and Skin Fibrosis in Systemic Sclerosis

Blaž Burja1, Ishani Banik2, Shervin Assassi3, Michael Whitfield4, J. Matthew Mahoney5, Andreja Erman6, Matija Tomšič7, Mitchell P. Levesque2, Snežna Sodin-Šemrl7, Gabriela Kania8, Hubert Rehrauer9, Ziga Rotar7, Oliver Distler10, Katja Lakota11 and Mojca Frank-Bertoncelj10, 1Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich and Department of Rheumatology, University Medical Centre Ljubljana, Zurich, Switzerland, 2Department of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 3University of Texas McGovern Medical School at Houston, Houston, TX, 4Geisel School of Medicine, Lebanon, NH, 5Center for Quantitative Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, 6Institute for Cell Biology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 7Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 8Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 9Functional Genomics Center Zurich, ETH Zurich and University of Zurich, Zurich, Switzerland, 10Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland, 11Department of Rheumatology, University Medical Centre Ljubljana, Llubljana, Slovenia

Meeting: ACR Convergence 2021

Keywords: Fibroblasts, Dermal, Metabolism, Skin fibrosis, Systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 7, 2021

Session Title: Systemic Sclerosis & Related Disorders – Basic Science Poster (0541–0559)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Metabolic perturbations drive fibroblast-to-myofibroblast reprogramming and tissue fibrosis. Restoring perturbed metabolism might represent a new antifibrotic strategy. Here we explored the capacity of dimethyl-alpha-ketoglutarate (dm-aKG), a core cell metabolite, to regulate myofibroblast function and skin fibrosis in SSc.

Methods: To discover dysregulated genes, pathways, and cell types in SSc skin, we integrated skin transcriptomes of 76 SSc patients and 26 healthy controls (HC) from three different cohorts (GSE:45485, 59785, 9285/32413) using limma and GSEA. We deconvoluted cell types in bulk skin transcriptomes using human skin single-cell RNA-seq data1. We compared the dysregulated genes in SSc skin with RNA-seq data from cultured TGFβ-treated healthy human dermal fibroblasts (DF) and validated gene dysregulations with RNA-seq data from skin biopsies of the PRESS cohort with 48 early diffuse SSc patients and 33 HC. We studied the effects of dm-aKG on myofibroblast differentiation and pro-fibrotic activation in 2D and 3D cultures of SSc and HC DF treated or not with TGFβ. We analyzed gene (RNA-seq, qPCR) and protein (Western blot, ELISA) expression and contractile (collagen gel contraction), migratory (wound scratch assay, DF spheroids) and invasive (collagen gel invasion in DF spheroids) cell functions. Statistical significance was set at p< 0.05.

Results: Our deconvolution of skin transcriptomes demonstrated an enrichment of specific fibroblast populations in SSc vs. HC skin: COL6A5+COL18A1+ inflammatory fibroblasts and COL11+LAMC3+ myofibroblasts were highly abundant in SSc skin (Fig. 1A). TGFβ increased the expression of several marker genes of the COL11+LAMC3+ myofibroblasts (Fig. 1B). Meanwhile, dm-aKG decreased the TGFβ-induced LAMC3 and COL11 mRNA expression in cultured DF, suggesting that TGFβ might facilitate, while dm-aKG could repress the COL11+LAMC3+ myofibroblast expansion in SSc skin. We uncovered dysregulation of several aKG-associated metabolic pathways in SSc skin transcriptomes, such as mitochondrial respiration and oxidoreductase activity. Dm-aKG repressed the TGFβ-regulated pro-fibrotic responses and myofibroblast differentiation of DF as measured by procollagen-1, fibronectin and aSMA protein reduction. Furthermore, dm-aKG reversed the TGFβ-induced increase of genes regulating cytoskeleton organization (NEXN, CAP2, ANTXR1, LIMCH1, TGM2), cell contraction (ANKRD1, OXTR, FZD2, DYSF, CSRP2) and extracellular matrix dynamics (COL10A1, COL11A1, MMP14, MMP3, ADAMTS4, MATN3, SULF1, HAPLN1). These genes were all upregulated in skin from early diffuse SSc patients (PRESS cohort). Most importantly, functional experiments confirmed the core role of dm-aKG in suppressing contractile, migratory and invasive properties of TGFβ-activated DF.

Conclusion: Dm-aKG reverses the dysregulated expression of myofibroblast-linked gene signatures of the SSc skin and potently represses core myofibroblast functions. Thus, dm-aKG could represent a new therapy to combat skin fibrosis in SSc.

1He H et al. J Allergy Clin Immunol 2020

(A) Expanded inflammatory fibroblasts and myofibroblasts in SSc skin. (B) TGFβ upregulates COL11+LAMC3+ myofibroblast marker genes in DF.


Disclosures: B. Burja, None; I. Banik, None; S. Assassi, Novartis, 2, Boehringer Ingelheim, 2, 5, 6, 12, Travel, Corbus, 2, Integrity Continuing Education, 6, Medscape, 6, Momenta, 5, CSL Behring, 2, Janssen, 5, Abbvie, 2; M. Whitfield, Celdara Medical, LLC, 2, 5, 8, 12, Scientific Founder, Bristol Myers Squibb, 2, 5, 6, Acceleron, 2, Corbus Pharmaceuticals, 2, 6, Abbvie, 6, Kadmon, 6; J. Mahoney, None; A. Erman, None; M. Tomšič, None; M. Levesque, None; S. Sodin-Šemrl, None; G. Kania, None; H. Rehrauer, None; Z. Rotar, None; O. Distler, AbbVie, 12, Project scoring fee for Rheumatology Grant, Amgen, 2, Eli Lilly, 2, Pfizer Inc, 2; K. Lakota, None; M. Frank-Bertoncelj, AbbVie, 5.

To cite this abstract in AMA style:

Burja B, Banik I, Assassi S, Whitfield M, Mahoney J, Erman A, Tomšič M, Levesque M, Sodin-Šemrl S, Kania G, Rehrauer H, Rotar Z, Distler O, Lakota K, Frank-Bertoncelj M. Metabolic Intermediate Dimethyl-Alpha-Ketoglutarate Is a Novel Repressor of Pathogenic Myofibroblast Reprogramming and Skin Fibrosis in Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/metabolic-intermediate-dimethyl-alpha-ketoglutarate-is-a-novel-repressor-of-pathogenic-myofibroblast-reprogramming-and-skin-fibrosis-in-systemic-sclerosis/. Accessed February 3, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/metabolic-intermediate-dimethyl-alpha-ketoglutarate-is-a-novel-repressor-of-pathogenic-myofibroblast-reprogramming-and-skin-fibrosis-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences